Quick Takeaways
- ORBIMED ADVISORS LLC filed SCHEDULE 13G/A for C4 Therapeutics, Inc. Common Stock, par value $0.0001 per share (CCCC).
- Disclosed ownership: 6.6%.
- Date of event: 31 Mar 2025.
ORBIMED ADVISORS LLC - 31 Mar 2025 SCHEDULE 13G/A Report for C4 Therapeutics, Inc. Common Stock, par value $0.0001 per share (CCCC)
- Filing Manager
- ORBIMED ADVISORS LLC
- Reporting Manager
- OrbiMed Capital LLC
- Symbol
- CCCC
- Shares outstanding
- 70,539,394 shares
- Disclosed Ownership
- 4,655,600 shares
- Ownership
- 6.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2025, 20:09:15 UTC
- Date of event
- 31 Mar 2025
- Next filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ORBIMED ADVISORS LLC disclosed 6.6% ownership in C4 Therapeutics, Inc. Common Stock, par value $0.0001 per share (CCCC) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2025, 20:09.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 3.1% | 2,174,700 | 0 | 2,174,700 | /s/ Carl L. Gordon | Carl L. Gordon / Member | |
| OrbiMed Capital LLC | 6.6% | 4,655,600 | 4,655,600 | 0 | /s/ Carl L. Gordon | Carl L. Gordon / Member |